PPARδ is the Food and Drug Administration (FDA) approved drug target [64], while PPARγ have been investigated in several clinical trials for their potential in treating non-alcoholic fatty liver disease (NAFLD). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.